Skip to main content

Table 1 Patient characteristics and biopsy outcomes

From: Cancer detection rate of prebiopsy MRI with subsequent systematic and targeted biopsy are superior to non-targeting systematic biopsy without MRI in biopsy naïve patients: a retrospective cohort study

 

MRI (+)

n = 215

MRI (−)

n = 281

p Value

Median

IQR

Median

IQR

Age

68

(62–72)

68

(63–72)

0.21

PSA (ng/mL)

6.4

(5.2–8.8)

6.7

(5.5–9.4)

0.25

Prostate volume (cm3)

27.7

(21.0–36.0)

32.0

(23.0–45.8)

0.0002

PSA density (ng/mL/cm3)

0.22

(0.16–0.34)

0.23

(0.16–0.34)

0.79

DRE positive, n (%)

44

(20.5)

41

(14.6)

0.09

TRUS positive, n (%)

32

(14.9)

29

(10.3)

0.13

MRI type, n (%)

 1.5 Tesla

161

(74.9%)

(−)

  

 3 Tesla

54

(25.1%)

(−)

  

Prostate cancer, n (%)

119

(55.3%)

118

(42.0%)

0.004

Gleason sum, n (%)

 3 + 3

34

(15.8%)

42

(14.9%)

0.80

 3 + 4

43

(20.0%)

40

(14.5%)

0.08

 4 + 3

16

(7.4%)

11

(3.9%)

0.11

 8 or more

26

(12.1%)

25

(8.9%)

0.30

Clinical significance, n (%)

 Insignificant cancer

20

(9.3%)

19

(6.8%)

0.32

 Significant cancer

99

(46.0%)

99

(35.2%)

0.016

Cancer positive cores

3

(1.25–5)

2

(1–4)

0.28

Back to article page

BMC Urology

ISSN: 1471-2490

Contact us